Elvaston, an entrepreneur-led private equity firm, has sold its participation in Magnolia International to GENUI. The investment company has acquired a majority stake in Magnolia and will injects significant growth capital into the company. Magnolia
Tags :Alexander Gutmans
The Swiss pharmaceutical BioVersys has raised CHF 24.2 million in a first closing of its Series C round. This first closing was significantly oversubscribed by both existing and new investors from diverse geographies. The company intends
ImmunOs Therapeutics has closed an oversubscribed Series B financing round totaling USD 74 million. The round was led by new investors Samsara BioCapital, Lightspeed Venture Partners, and Gimv, and joined by new investors Mission BioCapital, GL
DSM and Firmenich have entered into a business combination agreement to establish the leading creation and innovation partner in nutrition, beauty and well-being. The Dutch specialty chemicals maker has said that this merge with Swiss
Swiss biotech company, Engimmune Therapeutics completes its seed financing round raising CHF 15.5 million, co-led by Pureos Bioventures and Novo Holdings with incubation from BaseLaunch. Engimmune Therapeutics is a platform company using cutting-edge technologies
Versant Ventures debut Cimeio Therapeutics, a biotechnology company developing a novel approach to cell therapies. Versant has made a USD 50m Series A commitment to Cimeio, which is the most recent start-up to emerge from
kooky, a brand of Zurich-based CEBS, focuses on developing alternative solutions for disposable tableware, has secured an addition EURO 6 million for expansion to Germany and Austria. Early-stage venture capital fund, UVC Partners acted as main
Memo Therapeutics, specialists in the field of antibody discovery and development, has closed an oversubscribed Series B financing round led by Swisscanto Invest at CHF37 million after securing an additional CHF23 million from a combination
Alloy Therapeutics, a Boston based biotechnology ecosystem company, has entered into a definitive agreement to acquire deepCDR Biologics, a privately held Basel based developer of deep learning technology for antibody discovery and optimisation. Alloy will
GlycoEra has successfully completed a CHF 45 million Series A financing round, co-led by 5AM Ventures, Roche Venture Fund and Sofinnova Partners. LimmaTech Biologics, from which GlycoEra was spun-out, also participated in this round. GlycoEra’s